Abstract:Ubiquitination, an important type of protein posttranslational modification (PTM), plays a crucial role in controlling substrate degradation and subsequently mediates the "quantity" and "quality" of various proteins, serving to ensure cell homeostasis and guarantee life activities. The regulation of ubiquitination is multifaceted and works not only at the transcriptional and posttranslational levels (phosphorylation, acetylation, methylation, etc.) but also at the protein level (activators or repressors). When regulatory mechanisms are aberrant, the altered biological processes may subsequently induce serious human diseases, especially various types of cancer. In tumorigenesis, the altered biological processes involve tumor metabolism, the immunological tumor microenvironment (TME), cancer stem cell (CSC) stemness and so on. With regard to tumor metabolism, the ubiquitination of some key proteins such as RagA, mTOR, PTEN, AKT, c-Myc and P53 significantly regulates the activity of the mTORC1, AMPK and PTEN-AKT signaling pathways. In addition, ubiquitination in the TLR, RLR and STING-dependent signaling pathways also modulates the TME. Moreover, the ubiquitination of core stem cell regulator triplets (Nanog, Oct4 and Sox2) and members of the Wnt and Hippo-YAP signaling pathways participates in the maintenance of CSC stemness. Based on the altered components, including the proteasome, E3 ligases, E1, E2 and deubiquitinases (DUBs), many molecular targeted drugs have been developed to combat cancer. Among them, small molecule inhibitors targeting the proteasome, such as bortezomib, carfilzomib, oprozomib and ixazomib, have achieved tangible success. In addition, MLN7243 and MLN4924 (targeting the E1 enzyme), Leucettamol A and CC0651 (targeting the E2 enzyme), nutlin and MI-219 (targeting the E3 enzyme), and compounds G5 and F6 (targeting DUB activity) have also shown potential in preclinical cancer treatment. In this review, we summarize the latest progress in understanding the substrates for ubiquitination and their special functions in tumor metabolism regulation, TME modulation and CSC stemness maintenance. Moreover, potential therapeutic targets for cancer are reviewed, as are the therapeutic effects of targeted drugs.

The mechanism of UNC-51-like kinase 1 and the applications of small molecule modulators in cancer treatment

Discovery of a small molecule targeting ULK1-modulated cell death of triple negative breast cancer in vitro and in vivo

A patent review of UNC-51-like kinase 1/2 inhibitors (2019–present)

Autophagy Regulators As Potential Cancer Therapeutic Agents: A Review

Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells

Regulation of autophagy in tumor cells and application of targeting autophagy in cancer

The Molecular Mechanism of Autophagy Associated with Cancers

Mechanisms of autophagy and relevant small-molecule compounds for targeted cancer therapy

Targeting Autophagy with Natural Compounds in Cancer: A Renewed Perspective from Molecular Mechanisms to Targeted Therapy

Discovery of human autophagy initiation kinase ULK1 inhibitors by multi-directional in silico screening strategies

CK1δ/ε inhibition induces ULK1-mediated autophagy in tumorigenesis

Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Small‐Molecule Regulators of Autophagy and Their Potential Therapeutic Applications

Autophagy inhibitors for cancer therapy: Small molecules and nanomedicines

Autophagy Regulators in Cancer

Discovery of 5-bromo-4-phenoxy-N-phenylpyrimidin-2-amine derivatives as novel ULK1 inhibitors that block autophagy and induce apoptosis in non-small cell lung cancer

The role of ubiquitination in tumorigenesis and targeted drug discovery

Physiological functions of ULK1/2

An autophagy-independent role of ULK1/ULK2 in mechanotransduction and breast cancer cell migration

Development of potent and selective ULK1/2 inhibitors based on 7-azaindole scaffold with favorable in vivo properties

Autophagy modulation in cancer therapy